These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31582835)

  • 21. P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression.
    Zhang EB; Yin DD; Sun M; Kong R; Liu XH; You LH; Han L; Xia R; Wang KM; Yang JS; De W; Shu YQ; Wang ZX
    Cell Death Dis; 2014 May; 5(5):e1243. PubMed ID: 24853421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes.
    Hernando H; Gelato KA; Lesche R; Beckmann G; Koehr S; Otto S; Steigemann P; Stresemann C
    Mol Cancer Ther; 2016 Feb; 15(2):287-98. PubMed ID: 26590165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of BAP1 function leads to EZH2-dependent transformation.
    LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
    Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MUC1-C activates EZH2 expression and function in human cancer cells.
    Rajabi H; Hiraki M; Tagde A; Alam M; Bouillez A; Christensen CL; Samur M; Wong KK; Kufe D
    Sci Rep; 2017 Aug; 7(1):7481. PubMed ID: 28785086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting EZH2-mediated methylation of histone 3 inhibits proliferation of pediatric acute monocytic leukemia cells
    Al-Ghabkari A; Narendran A
    Cancer Biol Ther; 2021 Apr; 22(4):333-344. PubMed ID: 33978549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
    Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
    Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone trimethylation of the p53 gene by expression of a constitutively active prolactin receptor in prostate cancer cells.
    Tan D; Tan S; Zhang J; Tang P; Huang J; Zhou W; Wu S
    Chin J Physiol; 2013 Oct; 56(5):282-90. PubMed ID: 24032713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
    Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
    Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer.
    Chinaranagari S; Sharma P; Chaudhary J
    Oncotarget; 2014 Aug; 5(16):7172-82. PubMed ID: 25115397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A model for transmission of the H3K27me3 epigenetic mark.
    Hansen KH; Bracken AP; Pasini D; Dietrich N; Gehani SS; Monrad A; Rappsilber J; Lerdrup M; Helin K
    Nat Cell Biol; 2008 Nov; 10(11):1291-300. PubMed ID: 18931660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting B7‑H3 through EZH2 inhibition in MYC‑positive Group 3 medulloblastoma.
    Shishido K; Purvis IJ; Velpula KK; Venkataraman S; Vibhakar R; Asuthkar S
    Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37114557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.
    Fu Y; Chen J; Pang B; Li C; Zhao J; Shen K
    Cell Biochem Biophys; 2015 Jan; 71(1):105-12. PubMed ID: 25077680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.
    Gall Trošelj K; Novak Kujundzic R; Ugarkovic D
    Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HBP1-mediated Regulation of p21 Protein through the Mdm2/p53 and TCF4/EZH2 Pathways and Its Impact on Cell Senescence and Tumorigenesis.
    Chen Y; Pan K; Wang P; Cao Z; Wang W; Wang S; Hu N; Xue J; Li H; Jiang W; Li G; Zhang X
    J Biol Chem; 2016 Jun; 291(24):12688-12705. PubMed ID: 27129219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2.
    Burdach S; Plehm S; Unland R; Dirksen U; Borkhardt A; Staege MS; Müller-Tidow C; Richter GH
    Cell Cycle; 2009 Jul; 8(13):1991-6. PubMed ID: 19502792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
    Li H; Cai Q; Godwin AK; Zhang R
    Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of H3K27 Trimethylation Promotes Radiotherapy Resistance in Medulloblastoma and Induces an Actionable Vulnerability to BET Inhibition.
    Gabriel N; Balaji K; Jayachandran K; Inkman M; Zhang J; Dahiya S; Goldstein M
    Cancer Res; 2022 May; 82(10):2019-2030. PubMed ID: 35315927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
    McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
    Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation.
    Wilson BG; Wang X; Shen X; McKenna ES; Lemieux ME; Cho YJ; Koellhoffer EC; Pomeroy SL; Orkin SH; Roberts CW
    Cancer Cell; 2010 Oct; 18(4):316-28. PubMed ID: 20951942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI1.
    Zhu D; Hunter SB; Vertino PM; Van Meir EG
    Cancer Res; 2011 Sep; 71(17):5859-70. PubMed ID: 21724586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.